Science-Based Technology

Backed by Science

The Allurion program was developed through peer-reviewed clinical studies and 15 years of research.

How Allurion Was Born

2009 — Harvard, Boston. Dr. Shantanu Gaur and Dr. Samuel Levy began working on a question at Harvard Medical School: "Can an effective weight-management tool be built without endoscopy or surgery?"

After years of research and development, the swallowable capsule technology became reality. The first placement took place in 2015.

As of 2026, Allurion has been used by more than 200,000 patients in over 60 countries. FDA PMA approval was granted in February 2026.

2009

Research began at Harvard

2015

First clinical placement

2020

50,000+ placements worldwide

2024

CE Mark renewed (MDR)

2026

FDA PMA Class III Approval

15 years of research,
200,000+ placements.

Clinical Studies

Multicenter StudyN = 1,770 patients

Ienca et al. — 1,770 Consecutive Patients

Obesity Surgery, 2020

A multicenter retrospective study conducted at 19 centers. Data from 1,770 consecutive patients in the procedure-less swallowable balloon program. Mean TBWL of 14.9% and a strong safety profile were confirmed.

New — February 2026N = 76 patients

Allurion + Tirzepatide Combination

Allurion, February 2026

The first study combining Allurion with the GLP-1 receptor agonist tirzepatide. A synergistic effect was observed, with a mean TBWL of 23% at 12 months (preliminary results).

23% TBWL — Preliminary Results
Allurion Technologies, 2026
Meta-analysisN = 3,771 patients, 18 RCTs

Weight Regain After GLP-1 Discontinuation

EClinicalMedicine / Lancet, 2025

A mean regain of +5.63 kg was observed when GLP-1 medications were discontinued. This finding underlines the importance of long-term weight-management strategies after drug therapy.

+5.63 kg Regain (after GLP-1 discontinuation)
PMID 41399474 — PubMed
Clinical StudyProspective cohort

IGB + Semaglutide Synergy

Obesity Surgery, 2025

The combination of an intragastric balloon with semaglutide was shown to create a synergistic effect, with significant additional weight loss compared with either approach alone.

Synergistic Effect Confirmed
PMID 41212463 — PubMed
Real-World DataN = 200,000+ placements, 60+ countries

Global Safety Profile

Allurion Technologies, 2026

Real-world safety data from more than 200,000 placements. High tolerability and a low rate of serious adverse events. The most common side effects are transient nausea and discomfort.

200,000+ Placements Worldwide
Allurion.com, 2026

Average values do not represent individual results. TBWL = Total Body Weight Loss. Every clinical outcome varies from person to person.

Is It Right for You?

Find out with a free initial consultation.

Free Assessment
Book a Free Consultation